199 related articles for article (PubMed ID: 33318562)
1. Minimal system for assembly of SARS-CoV-2 virus like particles.
Swann H; Sharma A; Preece B; Peterson A; Eldredge C; Belnap DM; Vershinin M; Saffarian S
Sci Rep; 2020 Dec; 10(1):21877. PubMed ID: 33318562
[TBL] [Abstract][Full Text] [Related]
2. The SARS-CoV-2 envelope and membrane proteins modulate maturation and retention of the spike protein, allowing assembly of virus-like particles.
Boson B; Legros V; Zhou B; Siret E; Mathieu C; Cosset FL; Lavillette D; Denolly S
J Biol Chem; 2021; 296():100111. PubMed ID: 33229438
[TBL] [Abstract][Full Text] [Related]
3. Assembly and Entry of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2): Evaluation Using Virus-Like Particles.
Kumar B; Hawkins GM; Kicmal T; Qing E; Timm E; Gallagher T
Cells; 2021 Apr; 10(4):. PubMed ID: 33918600
[TBL] [Abstract][Full Text] [Related]
4. Small Structural Proteins E and M Render the SARS-CoV-2 Pseudovirus More Infectious and Reveal the Phenotype of Natural Viral Variants.
Wang HI; Chuang ZS; Kao YT; Lin YL; Liang JJ; Liao CC; Liao CL; Lai MMC; Yu CY
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445789
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles.
Plescia CB; David EA; Patra D; Sengupta R; Amiar S; Su Y; Stahelin RV
J Biol Chem; 2021; 296():100103. PubMed ID: 33214224
[TBL] [Abstract][Full Text] [Related]
6. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity.
Zhang L; Jackson CB; Mou H; Ojha A; Peng H; Quinlan BD; Rangarajan ES; Pan A; Vanderheiden A; Suthar MS; Li W; Izard T; Rader C; Farzan M; Choe H
Nat Commun; 2020 Nov; 11(1):6013. PubMed ID: 33243994
[TBL] [Abstract][Full Text] [Related]
8. Development, production and characterization of SARS-CoV-2 virus-like particles (Coronaviridae:
Latyshev OE; Zaykova ON; Eliseeva OV; Savochkina TE; Chernoryzh YY; Syroeshkin AV; Petrov GV; Vorkunova GK; Larichev VF; Fediakina IT; Cherepushkin SA; Tsibezov VV; Yuzhakova KA; Kulikova NY; Lebedeva VV; Yakunin DY; Kozlova AA; Baranets MS; Yurlov KI; Lesnova EI; Grebennikova TV
Vopr Virusol; 2024 May; 69(2):175-186. PubMed ID: 38843023
[TBL] [Abstract][Full Text] [Related]
9. Development of Fluorescence-Tagged SARS-CoV-2 Virus-like Particles by a Tri-Cistronic Vector Expression System for Investigating the Cellular Entry of SARS-CoV-2.
Chang YS; Chu LW; Chen ZY; Wu JS; Su WC; Yang CJ; Ping YH; Lin CW
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560829
[TBL] [Abstract][Full Text] [Related]
10. Properties of Coronavirus and SARS-CoV-2.
Malik YA
Malays J Pathol; 2020 Apr; 42(1):3-11. PubMed ID: 32342926
[TBL] [Abstract][Full Text] [Related]
11. Mammalian cells-based platforms for the generation of SARS-CoV-2 virus-like particles.
Elfayres G; Paswan RR; Sika L; Girard MP; Khalfi S; Letanneur C; Milette K; Singh A; Kobinger G; Berthoux L
J Virol Methods; 2023 Dec; 322():114835. PubMed ID: 37871706
[TBL] [Abstract][Full Text] [Related]
12. Topography, Spike Dynamics, and Nanomechanics of Individual Native SARS-CoV-2 Virions.
Kiss B; Kis Z; Pályi B; Kellermayer MSZ
Nano Lett; 2021 Mar; 21(6):2675-2680. PubMed ID: 33474931
[TBL] [Abstract][Full Text] [Related]
13. Construction of SARS-CoV-2 virus-like particles in plant.
Moon KB; Jeon JH; Choi H; Park JS; Park SJ; Lee HJ; Park JM; Cho HS; Moon JS; Oh H; Kang S; Mason HS; Kwon SY; Kim HS
Sci Rep; 2022 Jan; 12(1):1005. PubMed ID: 35046461
[TBL] [Abstract][Full Text] [Related]
14. RG203KR Mutations in SARS-CoV-2 Nucleocapsid: Assessing the Impact Using a Virus-Like Particle Model System.
Raheja H; Das S; Banerjee A; P D; C D; Mukhopadhyay D; Ramachandra SG; Das S
Microbiol Spectr; 2022 Aug; 10(4):e0078122. PubMed ID: 35862952
[TBL] [Abstract][Full Text] [Related]
15. Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System.
Xu R; Shi M; Li J; Song P; Li N
Front Bioeng Biotechnol; 2020; 8():862. PubMed ID: 32850726
[TBL] [Abstract][Full Text] [Related]
16. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.
Bhowmik D; Nandi R; Jagadeesan R; Kumar N; Prakash A; Kumar D
Infect Genet Evol; 2020 Oct; 84():104451. PubMed ID: 32640381
[TBL] [Abstract][Full Text] [Related]
17. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates.
Kang YF; Sun C; Zhuang Z; Yuan RY; Zheng Q; Li JP; Zhou PP; Chen XC; Liu Z; Zhang X; Yu XH; Kong XW; Zhu QY; Zhong Q; Xu M; Zhong NS; Zeng YX; Feng GK; Ke C; Zhao JC; Zeng MS
ACS Nano; 2021 Feb; 15(2):2738-2752. PubMed ID: 33464829
[TBL] [Abstract][Full Text] [Related]
18. Human Surfactant Protein D Binds Spike Protein and Acts as an Entry Inhibitor of SARS-CoV-2 Pseudotyped Viral Particles.
Hsieh MH; Beirag N; Murugaiah V; Chou YC; Kuo WS; Kao HF; Madan T; Kishore U; Wang JY
Front Immunol; 2021; 12():641360. PubMed ID: 34054808
[TBL] [Abstract][Full Text] [Related]
19. A cell based assay using virus-like particles to screen AM type mimics for SARS-CoV-2 neutralisation.
Gaur NK; Urankar S; Sengupta D; Chepuri VR; Makde RD; Kulkarni K
Biochem Biophys Res Commun; 2024 Jul; 718():150082. PubMed ID: 38735141
[TBL] [Abstract][Full Text] [Related]
20. Optimized production and fluorescent labeling of SARS-CoV-2 virus-like particles.
Gourdelier M; Swain J; Arone C; Mouttou A; Bracquemond D; Merida P; Saffarian S; Lyonnais S; Favard C; Muriaux D
Sci Rep; 2022 Aug; 12(1):14651. PubMed ID: 36030323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
